Sinovac Biotech (SVA) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- CoreWeave stock drops on dilution fears and debt concerns
- SpaceX to acquire Grain Management's 800 MHz spectrum portfolio
- Oracle and these 6 stocks are newest addition to Mizuho Top Picks list
- Anthropic launches cyber defense program for infrastructure and open-source
- Devon Energy to sell Eagle Ford assets to Crescent Energy for $4.2B
Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results
April 20, 2015 6:12 AM EDTBEIJING, April 20, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2014.
Fourth Quarter 2014 Financial Highlights
(Compared to the fourth quarter 2013)
Quarterly sales were $20.3 million, a decrease of 11.4% from $22.9 million in the prior year period. Excluding revenue recognized from the stockpiling of H5N1 pandemic influenza vaccine of $0.1 million in the fourth quarter of 2014 and $7.2 million in the fourth quarter of 2013, the Company's... More


